Continue reading this on our app for a better experience

Open in App
Home News Deals, joint ventures & alliances

SAM Holdings partners with Australia-based EnGeneIC to bring latest cancer treatment innovation to Singapore

Khairani Afifi Noordin
Khairani Afifi Noordin • 2 min read
SAM Holdings partners with Australia-based EnGeneIC to bring latest cancer treatment innovation to Singapore
SAM Holdings will collaborate with EnGeneIC on a profit-sharing basis. Photo: Albert Chua/The Edge Singapore
Font Resizer
Share to Whatsapp
Share to Facebook
Share to LinkedIn
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Catalist-listed Singapore Institute of Advanced Medicine Holdings (SAM Holdings) has entered into a strategic partnership with Australia-based biopharmaceutical company EnGeneIC.

Under the partnership, SAM Holdings will collaborate with EnGeneIC on a profit-sharing basis for manufacturing and distribution of anti-cancer products based on the latter’s proprietary technology platform, EnGeneIC Dream Vector (EDV). The partnership will also involve the development of EDV-based theranostics for use in the imaging and treatment of various cancers.

Among others, SAM Holdings will help EnGeneIC secure funding and regulatory authorisations for building a manufacturing plant in Singapore to manufacture EDV-based products and conduct clinical trials in the city-state. In turn, SAM Holdings will be granted exclusive distribution and marketing rights of these products in 17 countries within Asia. 

SAM Holdings will also collaborate with EnGeneIC for pre-clinical testing of EDV-based theranostics as well as obtain the regulatory approval for its commercialisation and sale. Subsequently, the company will be granted exclusive distribution rights worldwide for EDV-based theranostics.

“We have always been committed to providing our patients with easier access to the latest cancer treatment technologies and our partnership with EnGeneIC is another step forward in that direction,” says SAM Holdings executive director, CEO and founder Dr Djeng Shih Kien.

Shares in SAM Holdings closed 0.8 cents lower or 6.78% down on June 10 at 11 cents.

See also: Temasek’s Seviora to acquire minority stake in Hong Kong-based ADM Capital

 

×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2024 The Edge Publishing Pte Ltd. All rights reserved.